Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 219

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Radiomic subtyping improves disease stratification beyond key molecular, clinical, and standard imaging characteristics in patients with glioblastoma

Open access
Kickingereder, Philipp, Neuberger, Ulf, Bonekamp, David, Piechotta, Paula L, Götz, Michael, Wick, Antje, Sill, Martin, Kratz, Annekathrin, Shinohara, Russell T, Jones, David T W, Radbruch, Alexander, Muschelli, John, Unterberg, Andreas, Debus, Jürgen, Schlemmer, Heinz-Peter, Herold-Mende, Christel, Pfister, Stefan, von Deimling, Andreas, Wick, Wolfgang, Capper, David, Maier-Hein, Klaus H, Bendszus, Martin·2018·Neuro-Oncology

Abstract

Background: The purpose of this study was to analyze the potential of radiomics for disease stratification beyond key molecular, clinical, and standard imaging features in patients with glioblastoma. Methods: Quantitative imaging features (n = 1043) were extracted from the multiparametric MRI of 181 patients with newly diagnosed glioblastoma prior to standard-of-care treatment (allocated to a discovery and a validation set, 2:1 ratio). A subset of 386/1043 features were identified as reproducible (in an independent MRI test-retest cohort) and selected for analysis. A penalized Cox model with 10-fold cross-validation (Coxnet) was fitted on the discovery set to construct a radiomic signature for predicting progression-free and overall survival (PFS and OS). The incremental value of a radiomic signature beyond molecular (O6-methylguanine-DNA methyltransferase [MGMT] promoter methylation, DNA methylation subgroups), clinical (patient's age, KPS, extent of resection, adjuvant treatment), and standard imaging parameters (tumor volumes) for stratifying PFS and OS was assessed with multivariate Cox models (performance quantified with prediction error curves). Results: The radiomic signature (constructed from 8/386 features identified through Coxnet) increased the prediction accuracy for PFS and OS (in both discovery and validation sets) beyond the assessed molecular, clinical, and standard imaging parameters (P ≤ 0.01). Prediction errors decreased by 36% for PFS and 37% for OS when adding the radiomic signature (compared with 29% and 27%, respectively, with molecular + clinical features alone). The radiomic signature was-along with MGMT status-the only parameter with independent significance on multivariate analysis (P ≤ 0.01). Conclusions: Our study stresses the role of integrating radiomics into a multilayer decision framework with key molecular and clinical features to improve disease stratification and to potentially advance personalized treatment of patients with glioblastoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/neuonc/nox188

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 219

Metadata

Authors
Kickingereder, P., Neuberger, U., Bonekamp, D., Piechotta, P. L., Götz, M., Wick, A., Sill, M., Kratz, A., Shinohara, R. T., Jones, D. T. W., Radbruch, A., Muschelli, J., Unterberg, A., Debus, J., Schlemmer, H.-P., Herold-Mende, C., Pfister, S., von Deimling, A., Wick, W., Capper, D., Maier-Hein, K. H., & Bendszus, M.
Venue
Neuro-Oncology
Published
2017-09-28
Volume
20
Issue
6
Pages
848-857
ISSN
  • 1522-8517 (ISSN-L)
  • 1523-5866
OpenAlex
W2757838129
Cited by
219
References
6
FWCI
13.06
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Radiomic subtyping improves disease stratification beyond key molecular, clinical, and standard imaging characteristics in patients with glioblastoma. https://app.cochat.ai/papers/10.1093/neuonc/nox188
The paper
Kickingereder, P., Neuberger, U., Bonekamp, D., Piechotta, P. L., Götz, M., Wick, A., Sill, M., Kratz, A., Shinohara, R. T., Jones, D. T. W., Radbruch, A., Muschelli, J., Unterberg, A., Debus, J., Schlemmer, H.-P., Herold-Mende, C., Pfister, S., von Deimling, A., Wick, W., . . . Bendszus, M. (2018). Radiomic subtyping improves disease stratification beyond key molecular, clinical, and standard imaging characteristics in patients with glioblastoma. Neuro-Oncology. https://doi.org/10.1093/neuonc/nox188

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.